CJC-1295 and ipamorelin are sold together because they press two different buttons on the same gland. CJC-1295 is a GHRH analogue — it mimics the hypothalamic signal that tells the pituitary to release growth hormone. Ipamorelin works on the ghrelin receptor, a separate switch that amplifies that release. Two inputs, one output, no competition between them.
The part almost nobody explains: the version with DAC keeps growth hormone elevated for days, while your body normally releases it in short pulses, mostly at night. That difference — pulsatile versus sustained — is the single most important thing to understand about this pairing, and it is why the “without DAC” version exists at all.
The growth hormone axis in 90 seconds
Growth hormone release is controlled by a three-part system:
- GHRH (growth hormone-releasing hormone) comes from the hypothalamus and tells the pituitary to release GH. This is the accelerator.
- Somatostatin, also from the hypothalamus, tells it to stop. This is the brake.
- Ghrelin, mostly from the stomach, acts on a separate pituitary receptor and amplifies the release. This is a second accelerator with its own pedal.
Downstream, GH travels to the liver and other tissues and triggers IGF-1, which does much of the actual work people associate with growth hormone. IGF-1 is also the number that stays elevated longest, and the one that carries the long-term questions.
Why two switches instead of one
CJC-1295 occupies the GHRH receptor. Ipamorelin occupies the ghrelin receptor. Because these are physically different receptors on the same cells, activating both produces a larger release than either alone — a pattern documented for GHRH and ghrelin-mimetic combinations generally.
There is a second, subtler argument. Ghrelin-receptor agonists also appear to blunt somatostatin, the brake. So one compound presses the accelerator while the other partially releases the brake. That is the mechanistic case for the pairing, and it is a genuinely reasonable one — considerably better reasoned than most peptide stacks.
Neither compound introduces growth hormone from outside. Both ask your own pituitary to release more of its own. That is the main structural difference from synthetic HGH, and it is also the ceiling: the response is limited by what the gland can actually produce.
CJC-1295, and what DAC actually changes
CJC-1295 is a modified GHRH fragment developed by ConjuChem, a Montréal company. The modification that matters is the Drug Affinity Complex (DAC): a chemical linker that makes the peptide bind to albumin in the blood. Albumin shields it from breakdown, turning a compound that would last minutes into one that lasts days.
| CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) | |
|---|---|---|
| Half-life | 5.8 to 8.1 days (measured in humans) | Roughly 30 minutes (estimates vary) |
| GH pattern | Raised baseline for days | Short pulse, then back to baseline |
| IGF-1 after one dose | Elevated 1.5–3× for 9 to 11 days | Brief |
| Human trial data | Phase 1 and phase 2 | Essentially none published |
| Can you stop it quickly? | No. It is in the system for over a week. | Yes, effectively |
Those numbers come from Teichman and colleagues, published in the Journal of Clinical Endocrinology & Metabolism in 2006: two randomized, placebo-controlled, double-blind trials in healthy adults. A single injection raised mean GH 2- to 10-fold for six days or more, and with repeated doses IGF-1 stayed above baseline for up to 28 days.
Ipamorelin, and why it was called “clean”
Ipamorelin is a five-amino-acid peptide developed by Novo Nordisk in the 1990s. Older compounds in the same family — GHRP-6 and GHRP-2 — also raised cortisol and prolactin and caused strong hunger. In its original 1998 characterization, ipamorelin released growth hormone without a meaningful rise in ACTH or cortisol, even at high doses in animals.
That selectivity is where the “clean secretagogue” reputation comes from. It is a real finding, and it is also narrower than people assume: it is a statement about which hormones are affected, not a claim of no side effects. Anything that raises GH also raises IGF-1, and that is where the open questions live.
Pulsatile vs sustained: the real debate
This is the section most guides skip, and it is the most important one.
Your body does not release growth hormone in a steady stream. It releases it in pulses — bursts, largely during deep sleep, with low levels between them. Those troughs are not wasted time; receptor systems generally rely on periods of low signal to stay responsive. Constant stimulation of almost any hormone receptor tends to cause desensitization.
| Natural GH release | With DAC | Without DAC | |
|---|---|---|---|
| Pattern | Pulses, mostly nocturnal | Elevated baseline for days | Discrete pulses |
| Troughs between pulses | Yes | Largely flattened | Preserved |
| Resembles physiology | — | Less | More |
| Convenience | — | Higher — fewer injections | Lower |
DAC buys convenience and pays for it with physiological realism. Whether a flattened GH curve matters over months has never been measured in humans — no long-term study of either compound exists. But it is the reason informed people argue about DAC rather than treating it as a straightforward upgrade, and it is worth knowing before you choose a version.
What the human trials showed
| Compound | Study | Finding |
|---|---|---|
| CJC-1295 | Teichman 2006, healthy adults, 28 and 49 days | GH up 2–10× for 6+ days; IGF-1 up 1.5–3× for 9–11 days; half-life 5.8–8.1 days. “No serious adverse reactions were reported.” |
| Ipamorelin | Beck 2014, phase 2, 114 patients after bowel surgery | Adverse events 87.5% vs 94.8% on placebo — no excess over placebo. Efficacy endpoint not met (25.3 h vs 32.6 h, not significant). |
| The combination | — | No published human trial of the two together. |
The ipamorelin trial deserves a fair reading in both directions: it is genuine randomized placebo-controlled human safety data, which almost no research peptide has. It is also a failed efficacy trial, which is why ipamorelin never became a medicine.
The 2006 trial that was halted
ConjuChem ran a phase 2, placebo-controlled trial of weekly CJC-1295 in 192 people with HIV-associated abdominal obesity. In July 2006 the company halted the study after a participant died at a site in Argentina. At the time, the cause and its relationship to the drug were “being investigated.” No public finding linking the death to CJC-1295 was ever released, and the program did not continue.
A single death in a trial does not establish that a drug caused it, and deaths in trials of people with serious illness are not rare. But it is the reason CJC-1295 never received a full safety evaluation, and it is a fact most product pages omit entirely. You should have it.
Side effects of the whole class
Because no trial measured this combination, the most useful guide is the label of an approved drug in the same class. Tesamorelin (Egrifta) is a GHRH analogue approved in Canada since 2014, tested in over 800 patients against placebo:
| Effect | Tesamorelin | Placebo |
|---|---|---|
| Injection-site reactions | 17% | 6% |
| Joint pain | 13% | 11% |
| Muscle pain | 6% | 2% |
| Swelling of legs or feet | 6% | 2% |
| Tingling (paresthesia) | 5% | 2% |
| Carpal tunnel syndrome | 1% | 0% |
| HbA1c reaching 6.5%+ | 5% | 1% |
Most of that traces to one mechanism: growth hormone causes fluid retention, and fluid around joints and nerves produces aches, swelling and tingling. The blood-sugar line is the one that matters most — GH opposes insulin, so raising it pushes glucose up. Full detail in tesamorelin side effects and ipamorelin side effects.
Ipamorelin adds one of its own: it acts on the ghrelin receptor, so increased hunger is plausible, though reported as milder than with GHRP-6.
IGF-1, and the long-term question
IGF-1 promotes cell growth. That is the point, and it is also the concern. Higher IGF-1 levels have been associated with some cancers in population studies, which is why GH-raising drugs are contraindicated in people with active cancer. That is an association in epidemiology, not a demonstrated effect of these peptides — but it is the reason approved drugs in this class carry monitoring requirements, and neither CJC-1295 nor ipamorelin has any long-term human data at all.
Blend or separate vials?
| Pre-made blend | Two separate vials | |
|---|---|---|
| Convenience | One vial, one reconstitution | Two of each |
| Ratio control | Fixed by manufacturer | Independent |
| Half-life mismatch | Locked together despite very different clearance rates | Can be handled separately |
| If one causes a problem | Stop both | Stop one |
| COA | Must state the split per component | One COA each, easier to verify |
| Cost per total mg | Usually lower | Usually higher |
There is a real technical wrinkle here that does not exist with other blends: the two compounds have wildly different half-lives — days versus minutes. A fixed blend locks them to the same schedule anyway. That is a convenience trade-off worth understanding before you pick a format.
What it costs in Canada
| Product | Size | Price |
|---|---|---|
| CJC-1295 w/DAC | 2 mg | $31 |
| Ipamorelin | 5–10 mg | $40 |
| CJC/IPA blend | 10 mg total | $75 |
| Bacteriostatic water | 3–10 mL | $7 |
Full pricing across the catalogue is in what research peptides cost in Canada.
See the CJC/IPA blend and its COA →
How it compares to tesamorelin
| CJC-1295 | Ipamorelin | Tesamorelin | |
|---|---|---|---|
| Class | GHRH analogue | Ghrelin receptor agonist | GHRH analogue |
| Approved anywhere? | No | No | Yes — Health Canada 2014, for HIV-associated lipodystrophy |
| Human safety data | Phase 1; phase 2 halted | Phase 2, 114 patients | 800+ patients vs placebo |
| Duration | Days (with DAC) | Short | Daily dosing |
If what you want is the best-characterised GHRH analogue, it is tesamorelin — and it is available by prescription for its approved indication. Comparison in CJC-1295 vs tesamorelin vs ipamorelin.
Who this does not suit
- Anyone with diabetes or prediabetes. GH opposes insulin. The approved drug in this class raised HbA1c to the diabetes threshold in 5% of patients versus 1% on placebo.
- Anyone with active cancer or a significant history. GH-raising drugs are contraindicated in active malignancy.
- Anyone with a pituitary condition or prior pituitary surgery or radiation.
- Tested athletes. Both are prohibited at all times under WADA category S2.
- Anyone who may need to stop quickly. With DAC, the compound is in the system for over a week.
Common mistakes
- Not knowing whether you bought DAC or no-DAC. They behave completely differently. The product name and COA should say.
- Assuming “selective” means “no side effects.” It means no meaningful cortisol or prolactin rise. The GH class effects still apply.
- Ignoring blood sugar. The most measurable risk in this class, and the easiest to check.
- Treating the 2006 trial halt as irrelevant. It is why the compound has no complete safety evaluation.
- Buying a blend with no stated split. “10 mg blend” tells you nothing about the ratio.
- Expecting HGH-like results. These ask your own pituitary for more output; they do not add hormone from outside.
Legal status and sport
| Health Canada | Neither is authorized. Both CJC-1295 and ipamorelin are named in Health Canada’s April 9, 2026 public advisory on unauthorized injectable peptides, and both were among the products seized from Canada Peptide in 2025. The advisory states that “research use only” labelling does not make these products legal or exempt from regulatory requirements. |
|---|---|
| FDA (USA) | Neither is approved. CJC-1295 development stopped after 2006; ipamorelin development stopped after the 2014 phase 2 results. |
| WADA | Both prohibited at all times under S2 — GHRH analogues and GH secretagogues. No therapeutic use exemption, strict liability. |
Glossary
| GHRH | Growth hormone-releasing hormone. The hypothalamic signal that triggers GH release. |
| Secretagogue | Anything that causes a gland to secrete. Here, a compound that makes the pituitary release GH. |
| DAC | Drug Affinity Complex. The albumin-binding linker that extends CJC-1295’s half-life from minutes to days. |
| Somatostatin | The hypothalamic brake on GH release. |
| IGF-1 | Insulin-like growth factor 1. The downstream hormone that does much of GH’s work and stays elevated longest. |
| Pulsatile | Released in bursts rather than continuously — the natural pattern for GH. |
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
Why are CJC-1295 and ipamorelin sold together?
They act on two different receptors on the same pituitary cells: CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor. Activating both produces a larger growth hormone release than either alone, and ghrelin-receptor agonists also appear to blunt somatostatin, the brake on GH release.
What is the difference between CJC-1295 with and without DAC?
DAC is a linker that binds the peptide to albumin in the blood, giving a measured half-life of 5.8 to 8.1 days in humans. Without DAC, it acts for roughly 30 minutes and produces a short pulse instead of a sustained elevation.
Is CJC-1295 with DAC better than without?
Neither is established as better. DAC is far more convenient but flattens the natural pulsatile pattern of growth hormone release; the no-DAC version preserves pulses but requires more frequent administration. No long-term human study has compared them.
What are the side effects of CJC-1295 and ipamorelin?
No trial has measured the combination. Based on the approved GHRH analogue tesamorelin, expected class effects include injection-site reactions, joint and muscle pain, fluid retention, tingling and raised blood sugar. Ipamorelin may also increase hunger via the ghrelin receptor.
Does ipamorelin raise cortisol?
In its original 1998 characterization, ipamorelin released growth hormone without a meaningful rise in ACTH or cortisol, unlike the older secretagogues GHRP-6 and GHRP-2.
Do these peptides work like HGH?
No. They ask your own pituitary to release more of its own growth hormone, rather than introducing hormone from outside. The response is limited by what your gland can produce.
Why was the CJC-1295 trial stopped in 2006?
ConjuChem halted a phase 2 trial in 192 people after a participant died at a site in Argentina. The cause and its relationship to the drug were under investigation, no public finding linking the death to the drug was released, and development did not continue.
Did ipamorelin pass its clinical trial?
It passed on safety and failed on efficacy. In a 114-patient randomized phase 2 trial, adverse events were no more frequent than placebo, but the efficacy endpoint was not met, and development stopped.
Is the blend better than separate vials?
Neither is scientifically better. A blend is simpler and usually cheaper per milligram; separate vials let you control the ratio, which matters here because the two compounds have very different half-lives.
Do these affect blood sugar?
Growth hormone opposes insulin, so raising it can push glucose up. In trials of the approved GHRH analogue tesamorelin, HbA1c reached the diabetes threshold in 5% of patients versus 1% on placebo.
Are CJC-1295 and ipamorelin legal in Canada?
Neither is authorized by Health Canada. Both are named in its April 2026 advisory on unauthorized injectable peptides.
Are they banned in sport?
Yes. Both fall under WADA category S2, prohibited at all times, with strict liability.
Related reading
- CJC-1295 side effects
- Ipamorelin side effects
- CJC-1295 vs tesamorelin vs ipamorelin
- Tesamorelin side effects
- IGF-1 vs IGF-1 LR3
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. DOI
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PubMed
- Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014;29(12):1527–1534. DOI
- aidsmap. Lipodystrophy study halted after patient death. July 2006. aidsmap
- EGRIFTA (tesamorelin) prescribing information. Drugs.com
- Health Canada. Think twice before injecting peptides bought online. Public advisory, April 9, 2026. Health Canada
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use, and nothing in this article is medical advice or a dosing protocol. If you have diabetes, prediabetes or any history of cancer, talk to a doctor.